The remarkable response to ponatinib therapy in a child with blastic phase of chronic myeloid leukemia
Background. Chronic myeloid leukemia (CML) rarely occurs in children and adolescents, which shows more aggressive features like high risk of more advanced disease at the time of diagnosis. Suboptimal response to tyrosine kinase inhibitors (TKIs), adverse events, or advanced disease may impede...
Saved in:
| Main Authors: | Tekin Aksu, Şule Ünal, Fatma Gümrük |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
2020-06-01
|
| Series: | The Turkish Journal of Pediatrics |
| Subjects: | |
| Online Access: | https://turkjpediatr.org/article/view/469 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies
by: Tomasz Sacha, et al.
Published: (2025-01-01) -
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry
by: Timothy Devos, et al.
Published: (2025-12-01) -
Ponatinib/blinatumomab for relapsed Philadelphia chromosome-positive leukemia as a bridge to allogeneic transplantation
by: Yasutaka Sadaga, et al.
Published: (2025-12-01) -
Ponatinib-induced psoriasis treated with tildrakizumab
by: Kyle Mueller, BA, et al.
Published: (2025-08-01) -
A rare case of Klippel-Trenaunay syndrome presenting with chronic myeloid leukemia
by: Çağrı Coşkun, et al.
Published: (2023-02-01)